In this report, the EMEA Immune Checkpoint Inhibitors market is valued at USD XX million in 2019 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2019 and 2025.
Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Immune Checkpoint Inhibitors for these regions, from 2018 to 2025 (forecast)
Europe: Germany, France, UK, Russia, Italy and Benelux;
Middle East: Saudi Arabia, Israel, UAE and Iran;
Africa: South Africa, Nigeria, Egypt and Algeria.
EMEA Immune Checkpoint Inhibitors market competition by top manufacturers/players, with Immune Checkpoint Inhibitors sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
Bristol Myer Squibb
AstraZeneca
Merck & Co.
Roche / Genentech
Incyte Corporation
NewLink Genetics
ArGEN-X
Seattle Genetics
Pfizer
MacroGenics
Celldex Therapeutics
CureTech
Immutep
Innate Pharma
Sorrento Therapeutics
GlaxoSmithKline
GITR, Inc
On the basis of product, this report displays the sales volume (K Pcs), revenue (Million USD), product price (USD/Pcs), market share and growth rate of each type, primarily split into
PD-1/PD-L1
CTLA-4
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Pcs), market share and growth rate of Immune Checkpoint Inhibitors for each application, including
Lung Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Melanoma
Blood Cancer
Other
If you have any special requirements, please let us know and we will offer you the report as you want.
Table of Contents
EMEA (Europe, Middle East and Africa) Immune Checkpoint Inhibitors Market Report 2019
1 Immune Checkpoint Inhibitors Overview
1.1 Product Overview and Scope of Immune Checkpoint Inhibitors
1.2 Classification of Immune Checkpoint Inhibitors
1.2.1 EMEA Immune Checkpoint Inhibitors Market Size (Sales) Comparison by Type (2014-2024)
1.2.2 EMEA Immune Checkpoint Inhibitors Market Size (Sales) Market Share by Type (Product Category) in 2016
1.2.3 PD-1/PD-L1
1.2.4 CTLA-4
1.3 EMEA Immune Checkpoint Inhibitors Market by Application/End Users
1.3.1 EMEA Immune Checkpoint Inhibitors Sales (Volume) and Market Share Comparison by Application (2014-2024
1.3.2 Lung Cancer
1.3.3 Colorectal Cancer
1.3.4 Breast Cancer
1.3.5 Prostate Cancer
1.3.6 Melanoma
1.3.7 Blood Cancer
1.3.8 Other
1.4 EMEA Immune Checkpoint Inhibitors Market by Region
1.4.1 EMEA Immune Checkpoint Inhibitors Market Size (Value) Comparison by Region (2014-2024)
1.4.2 Europe Status and Prospect (2014-2024)
1.4.3 Middle East Status and Prospect (2014-2024)
1.4.4 Africa Status and Prospect (2014-2024)
1.5 EMEA Market Size (Value and Volume) of Immune Checkpoint Inhibitors (2014-2024)
1.5.1 EMEA Immune Checkpoint Inhibitors Sales and Growth Rate (2014-2024)
1.5.2 EMEA Immune Checkpoint Inhibitors Revenue and Growth Rate (2014-2024)
2 EMEA Immune Checkpoint Inhibitors Competition by Manufacturers/Players/Suppliers, Region, Type and Application
2.1 EMEA Immune Checkpoint Inhibitors Market Competition by Players/Manufacturers
2.1.1 EMEA Immune Checkpoint Inhibitors Sales Volume and Market Share of Major Players (2014-2019)
2.1.2 EMEA Immune Checkpoint Inhibitors Revenue and Share by Players (2014-2019)
2.1.3 EMEA Immune Checkpoint Inhibitors Sale Price by Players (2014-2019)
2.2 EMEA Immune Checkpoint Inhibitors (Volume and Value) by Type/Product Category
2.2.1 EMEA Immune Checkpoint Inhibitors Sales and Market Share by Type (2014-2019)
2.2.2 EMEA Immune Checkpoint Inhibitors Revenue and Market Share by Type (2014-2019)
2.2.3 EMEA Immune Checkpoint Inhibitors Sale Price by Type (2014-2019)
2.3 EMEA Immune Checkpoint Inhibitors (Volume) by Application
2.4 EMEA Immune Checkpoint Inhibitors (Volume and Value) by Region
2.4.1 EMEA Immune Checkpoint Inhibitors Sales and Market Share by Region (2014-2019)
2.4.2 EMEA Immune Checkpoint Inhibitors Revenue and Market Share by Region (2014-2019)
2.4.3 EMEA Immune Checkpoint Inhibitors Sales Price by Region (2014-2019)
3 Europe Immune Checkpoint Inhibitors (Volume, Value and Sales Price), by Players, Countries, Type and Application
3.1 Europe Immune Checkpoint Inhibitors Sales and Value (2014-2019)
3.1.1 Europe Immune Checkpoint Inhibitors Sales Volume and Growth Rate (2014-2019)
3.1.2 Europe Immune Checkpoint Inhibitors Revenue and Growth Rate (2014-2019)
3.2 Europe Immune Checkpoint Inhibitors Sales and Market Share by Type
3.3 Europe Immune Checkpoint Inhibitors Sales and Market Share by Application
3.4 Europe Immune Checkpoint Inhibitors Sales Volume and Value (Revenue) by Countries
3.4.1 Europe Immune Checkpoint Inhibitors Sales Volume by Countries (2014-2019)
3.4.2 Europe Immune Checkpoint Inhibitors Revenue by Countries (2014-2019)
3.4.3 Germany Immune Checkpoint Inhibitors Sales and Growth Rate (2014-2019)
3.4.4 France Immune Checkpoint Inhibitors Sales and Growth Rate (2014-2019)
3.4.5 UK Immune Checkpoint Inhibitors Sales and Growth Rate (2014-2019)
3.4.6 Russia Immune Checkpoint Inhibitors Sales and Growth Rate (2014-2019)
3.4.7 Italy Immune Checkpoint Inhibitors Sales and Growth Rate (2014-2019)
3.4.8 Benelux Immune Checkpoint Inhibitors Sales and Growth Rate (2014-2019)
4 Middle East Immune Checkpoint Inhibitors (Volume, Value and Sales Price), by Region, Type and Application
4.1 Middle East Immune Checkpoint Inhibitors Sales and Value (2014-2019)
4.1.1 Middle East Immune Checkpoint Inhibitors Sales Volume and Growth Rate (2014-2019)
4.1.2 Middle East Immune Checkpoint Inhibitors Revenue and Growth Rate (2014-2019)
4.2 Middle East Immune Checkpoint Inhibitors Sales and Market Share by Type
4.3 Middle East Immune Checkpoint Inhibitors Sales and Market Share by Application
4.4 Middle East Immune Checkpoint Inhibitors Sales Volume and Value (Revenue) by Countries
4.4.1 Middle East Immune Checkpoint Inhibitors Sales Volume by Countries (2014-2019)
4.4.2 Middle East Immune Checkpoint Inhibitors Revenue by Countries (2014-2019)
4.4.3 Saudi Arabia Immune Checkpoint Inhibitors Sales and Growth Rate (2014-2019)
4.4.4 Israel Immune Checkpoint Inhibitors Sales and Growth Rate (2014-2019)
4.4.5 UAE Immune Checkpoint Inhibitors Sales and Growth Rate (2014-2019)
4.4.6 Iran Immune Checkpoint Inhibitors Sales and Growth Rate (2014-2019)
5 Africa Immune Checkpoint Inhibitors (Volume, Value and Sales Price) by Players, Countries, Type and Application
5.1 Africa Immune Checkpoint Inhibitors Sales and Value (2014-2019)
5.1.1 Africa Immune Checkpoint Inhibitors Sales Volume and Growth Rate (2014-2019)
5.1.2 Africa Immune Checkpoint Inhibitors Revenue and Growth Rate (2014-2019)
5.2 Africa Immune Checkpoint Inhibitors Sales and Market Share by Type
5.3 Africa Immune Checkpoint Inhibitors Sales and Market Share by Application
5.4 Africa Immune Checkpoint Inhibitors Sales Volume and Value (Revenue) by Countries
5.4.1 Africa Immune Checkpoint Inhibitors Sales Volume by Countries (2014-2019)
5.4.2 Africa Immune Checkpoint Inhibitors Revenue by Countries (2014-2019)
5.4.3 South Africa Immune Checkpoint Inhibitors Sales and Growth Rate (2014-2019)
5.4.4 Nigeria Immune Checkpoint Inhibitors Sales and Growth Rate (2014-2019)
5.4.5 Egypt Immune Checkpoint Inhibitors Sales and Growth Rate (2014-2019)
5.4.6 Algeria Immune Checkpoint Inhibitors Sales and Growth Rate (2014-2019)
6 EMEA Immune Checkpoint Inhibitors Manufacturers/Players Profiles and Sales Data
6.1 Bristol Myer Squibb
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Immune Checkpoint Inhibitors Product Type, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 Bristol Myer Squibb Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2014-2019)
6.1.4 Main Business/Business Overview
6.2 AstraZeneca
6.2.1 Company Basic Information, Manufacturing Base and Competitors
6.2.2 Immune Checkpoint Inhibitors Product Type, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 AstraZeneca Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2014-2019)
6.2.4 Main Business/Business Overview
6.3 Merck & Co.
6.3.1 Company Basic Information, Manufacturing Base and Competitors
6.3.2 Immune Checkpoint Inhibitors Product Type, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Merck & Co. Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2014-2019)
6.3.4 Main Business/Business Overview
6.4 Roche / Genentech
6.4.1 Company Basic Information, Manufacturing Base and Competitors
6.4.2 Immune Checkpoint Inhibitors Product Type, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 Roche / Genentech Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2014-2019)
6.4.4 Main Business/Business Overview
6.5 Incyte Corporation
6.5.1 Company Basic Information, Manufacturing Base and Competitors
6.5.2 Immune Checkpoint Inhibitors Product Type, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 Incyte Corporation Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2014-2019)
6.5.4 Main Business/Business Overview
6.6 NewLink Genetics
6.6.1 Company Basic Information, Manufacturing Base and Competitors
6.6.2 Immune Checkpoint Inhibitors Product Type, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 NewLink Genetics Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2014-2019)
6.6.4 Main Business/Business Overview
6.7 ArGEN-X
6.7.1 Company Basic Information, Manufacturing Base and Competitors
6.7.2 Immune Checkpoint Inhibitors Product Type, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 ArGEN-X Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2014-2019)
6.7.4 Main Business/Business Overview
6.8 Seattle Genetics
6.8.1 Company Basic Information, Manufacturing Base and Competitors
6.8.2 Immune Checkpoint Inhibitors Product Type, Application and Specification
6.8.2.1 Product A
6.8.2.2 Product B
6.8.3 Seattle Genetics Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2014-2019)
6.8.4 Main Business/Business Overview
6.9 Pfizer
6.9.1 Company Basic Information, Manufacturing Base and Competitors
6.9.2 Immune Checkpoint Inhibitors Product Type, Application and Specification
6.9.2.1 Product A
6.9.2.2 Product B
6.9.3 Pfizer Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2014-2019)
6.9.4 Main Business/Business Overview
6.10 MacroGenics
6.10.1 Company Basic Information, Manufacturing Base and Competitors
6.10.2 Immune Checkpoint Inhibitors Product Type, Application and Specification
6.10.2.1 Product A
6.10.2.2 Product B
6.10.3 MacroGenics Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2014-2019)
6.10.4 Main Business/Business Overview
6.11 Celldex Therapeutics
6.12 CureTech
6.13 Immutep
6.14 Innate Pharma
6.15 Sorrento Therapeutics
6.16 GlaxoSmithKline
6.17 GITR, Inc
7 Immune Checkpoint Inhibitors Manufacturing Cost Analysis
7.1 Immune Checkpoint Inhibitors Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Immune Checkpoint Inhibitors
8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Immune Checkpoint Inhibitors Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Immune Checkpoint Inhibitors Major Manufacturers in 2016
8.4 Downstream Buyers
9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List
10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change
11 EMEA Immune Checkpoint Inhibitors Market Forecast (2019-2024)
11.1 EMEA Immune Checkpoint Inhibitors Sales, Revenue and Price Forecast (2019-2024)
11.1.1 EMEA Immune Checkpoint Inhibitors Sales and Growth Rate Forecast (2019-2024)
11.1.2 EMEA Immune Checkpoint Inhibitors Revenue and Growth Rate Forecast (2019-2024)
11.1.3 EMEA Immune Checkpoint Inhibitors Price and Trend Forecast (2019-2024)
11.2 EMEA Immune Checkpoint Inhibitors Sales, Revenue and Growth Rate Forecast by Region (2019-2024)
11.3 Europe Immune Checkpoint Inhibitors Sales, Revenue and Growth Rate Forecast by Region (2019-2024)
11.4 Middle Eastt Immune Checkpoint Inhibitors Sales, Revenue and Growth Rate Forecast by Region (2019-2024)
11.5 Africa Immune Checkpoint Inhibitors Sales, Revenue and Growth Rate Forecast by Region (2019-2024)
11.6 EMEA Immune Checkpoint Inhibitors Sales Forecast by Type (2019-2024)
11.7 EMEA Immune Checkpoint Inhibitors Sales Forecast by Application (2019-2024)
12 Research Findings and Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
Request Discount 
Inquire Before Buy
